Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Kairos Pharma Ltd. market cap is $2.04M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Kairos Pharma Ltd. 52 week high is $7.28 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Kairos Pharma Ltd. 52 week low is $0.3808 as of November 22, 2026.
Kairos Pharma Ltd. stock price today is $0.4359.
Kairos Pharma Ltd. stock price yesterday was $0.457.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Kairos Pharma Ltd.'s P/E ratio is -0.3.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Kairos Pharma Ltd. P/B ratio is 0.4193.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Kairos Pharma Ltd. 50-day moving average is $0.9482.